Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by
chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in
preventing hand-foot syndrome.
PURPOSE: This randomized clinical trial is studying pyridoxine to see how well it works
compared to a placebo in preventing hand-foot syndrome in patients who are receiving
liposomal doxorubicin for recurrent ovarian, fallopian tube, or peritoneal cancer, metastatic
breast cancer, or advanced endometrial cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Doxorubicin Liposomal doxorubicin Pyridoxal Pyridoxine Vitamin B 6